A histologic subtype is a classification of a disease based on how its cells look under a microscope. When a pathologist examines a tissue biopsy, the shape, arrangement, and behavior of the cells tell a story: two tumors in the same organ can look strikingly different at the cellular level, and those differences often predict how the disease will act, which treatments will work, and how likely a patient is to recover. The concept applies most often to cancer, where dozens of subtypes exist across different organs, but it also guides decisions in kidney disease, lung fibrosis, and other conditions where tissue architecture matters.
How Pathologists Determine a Subtype
The starting point is the tissue biopsy itself. A pathologist takes a thin slice, stains it, and examines it under a microscope. The most common stain, hematoxylin and eosin (H&E), turns cell nuclei blue and surrounding structures pink, revealing the overall architecture. In many cases, that basic view is enough: the cells clearly form glands, or they clearly form solid sheets, or they grow in a lacy web-like pattern. Each of those growth patterns corresponds to a recognized subtype.
When the microscopic appearance alone is ambiguous, pathologists turn to immunohistochemistry, a technique that uses antibodies to detect specific proteins on or inside cells. Different subtypes express different proteins, so a panel of stains can narrow the diagnosis. In a study of ampullary cancers (tumors at the junction of the bile duct and small intestine), adding a five-marker panel to standard H&E staining allowed pathologists to sort about 92% of cases into one of two main subtypes, up from a much lower success rate with H&E alone.1The American Journal of Surgical Pathology. The Utility of Immunohistochemistry in Subtyping Adenocarcinoma of the Ampulla of Vater A similar approach works in lung cancer, where a streamlined three-marker panel classified roughly 83% of ambiguous small biopsies into either adenocarcinoma or squamous cell carcinoma.2PubMed. A comprehensive immunohistochemistry algorithm for the histological subtyping of small biopsies obtained from non-small cell lung cancers
These tools exist because getting the subtype right has real consequences for the patient, and an incorrect label can mean the wrong drug, the wrong dose, or surgery that was never needed in the first place.
Why the Subtype Changes Which Treatment You Get
Lung cancer is the clearest example of how subtyping drives treatment decisions. The disease has three main histologic types, and the development of type-specific therapies has made accurate identification more important than ever.3PubMed Central. Lung Cancer Subtyping: A Short Review Two widely used drugs illustrate why. Bevacizumab, an anti-angiogenesis agent, is restricted to patients with nonsquamous non-small cell lung cancer because squamous tumors treated with it showed a dangerous association with severe pulmonary hemorrhage. Pemetrexed, a chemotherapy drug, is similarly restricted to nonsquamous patients because it simply works better in that group.4PubMed. The evolving role of histology in the management of advanced non-small-cell lung cancer A patient whose biopsy is labeled “squamous cell carcinoma” will not receive either drug. A patient whose biopsy is labeled “adenocarcinoma” may receive both. The subtype is essentially a gatekeeper for the treatment plan.
This pattern repeats across organs. In breast cancer, invasive lobular carcinoma (the second most common histologic subtype) differs from the more common invasive ductal carcinoma in how it responds to systemic therapy.5PubMed Central. Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications The two subtypes also spread to different parts of the body when they metastasize: ductal cancers tend to spread to the bone, while lobular cancers favor the peritoneum, ovaries, and gastrointestinal tract.6The ASCO Post. Lobular vs Ductal Breast Cancer: Distinctions in Management Knowing which subtype you’re dealing with tells clinicians where to look for recurrence and which surveillance strategies to prioritize.
Subtype and Prognosis Are Not Always the Same Conversation
It would be tidy if every histologic subtype came with a neatly different prognosis. Sometimes it does. In kidney cancer, modern genomic work has confirmed that the major histologic subtypes of renal cell carcinoma are genetically distinct, and survival differs meaningfully between them.7PubMed Central. Histological subtype of renal cell carcinoma significantly impacts survival in the era of partial nephrectomy In breast cancer, the special histologic types (accounting for up to a quarter of all invasive cases) carry distinctive biological features that correlate with specific genetic changes and clinical behaviors.8PubMed Central. Histological types of breast cancer: how special are they?
But the relationship between subtype and survival is not always straightforward. High-grade endometrial cancer illustrates the tension well. When researchers compared the three major high-grade subtypes treated with individualized protocols, five-year survival rates were 45%, 36%, and 50% for the different types, but those differences were not statistically significant. Stage at diagnosis mattered far more than subtype in predicting who would survive.9The American Journal of Surgical Pathology. Clinicopathologic Analysis of 187 High-grade Endometrial Carcinomas of Different Histologic Subtypes: Similar Outcomes Belie Distinctive Biologic Differences That said, the subtypes did differ in age at presentation, racial distribution, and where in the body they tended to spread, supporting the view that they are genuinely distinct diseases even when their survival curves converge.
This finding is counterintuitive but important: the subtype can tell you that a cancer is biologically different without necessarily telling you that the outcome will be different. Sometimes what matters more is the grade, the stage, or the genetic mutations driving the tumor. The subtype is one layer of information, valuable on its own but most powerful when combined with everything else.
When Histology Meets Molecular Testing
The last decade has seen a significant shift in how diseases are classified, especially in neuro-oncology. The 2021 World Health Organization classification of central nervous system tumors formally incorporated molecular genetics alongside histologic appearance, producing what pathologists call an “integrated diagnosis.”10PubMed Central. The WHO 2021 Classification of Central Nervous System tumours: a practical update on what neurosurgeons need to know—a minireview Under this system, a brain tumor diagnosis is layered: one level records how the tissue looks under the microscope, another records the tumor’s WHO grade, and another captures the key molecular findings. Two tumors that look identical on a slide might receive different names (and different treatment plans) because they carry different mutations.
This layered approach reflects a broader recognition that microscopic appearance and molecular biology do not always agree. A tumor that looks like a low-grade glioma under the microscope might harbor a molecular signature associated with aggressive behavior, or the reverse. The integrated framework captures both signals, giving oncologists a more precise prediction than either one alone.11PubMed. 2021 World Health Organization Classification of Brain Tumors Updated guidelines continue to expand the number of tumor types for which molecular characteristics are built into the classification itself.12Journal of Pathology and Translational Medicine. What’s new in neuropathology 2024: CNS WHO 5th edition updates
The same trend is emerging in other cancers. In pancreatic cancer, rare histologic variants and tumors lacking the typical KRAS mutation are now recognized as subgroups where targeted therapies may work, though most of the evidence remains early-stage.13Cancer Treatment Reviews. Targeted therapeutic strategies in rare subtypes of pancreatic cancer: Histology, molecular profiles, and emerging opportunities The direction is clear: histologic subtyping is not being replaced by molecular testing but merged with it.
The Difficulty of Getting It Right
Subtyping is not as objective as it might sound. Two experienced pathologists looking at the same tissue slide do not always agree on what they see, and that disagreement can matter clinically. In one study of lung adenocarcinoma patterns, agreement among reviewers on the dominant growth pattern was only moderate. For certain patterns, like the micropapillary subtype, agreement was particularly low.14Turkish Journal of Pathology. Interobserver Agreement Among Histological Patterns and Diagnosis in Lung Adenocarcinomas
Ovarian cancer offers another window into this challenge. When pathologists classified ovarian carcinoma subtypes, overall agreement was about 87% across all cases. But that number masked a big split: for tumors with typical, straightforward features, agreement was 100%. For tumors that showed internal heterogeneity and required multiple slides to evaluate, agreement dropped to around 64%.15PubMed Central. Selection of Representative Histologic Slides in Interobserver Reproducibility Studies: Insights from Expert Review for Ovarian Carcinoma Subtype Classification The tricky cases are the ones that need the diagnosis most, and they are also the ones where the diagnosis is least reliable.
Tumor heterogeneity compounds the problem. A single tumor can contain regions that look like different subtypes, and a biopsy captures only a small fraction of the mass. Current treatment decisions typically rely on the molecular characteristics of that limited sample, without fully accounting for how the tumor varies across its bulk or how it changes over time.16PubMed Central. Deciphering Tumour Heterogeneity: From Tissue to Liquid Biopsy Stereotactic brain biopsies, which sample only a thin cylinder of tissue, have historically encountered sampling errors where the biopsy hits a non-representative region and the pathologist sees only reactive tissue rather than the actual tumor.17PubMed. Accuracy of stereotactic brain tumor biopsy: comparison of the histologic findings in biopsy cylinders and resected tumor tissue
This is why second opinions in pathology exist and why they can have outsized consequences. In one review of prostate biopsies submitted before planned radical prostatectomy, pathology re-review reversed the cancer diagnosis in seven patients. Six of those men were ultimately judged not to have adenocarcinoma, and their surgeries were cancelled. The cost of reviewing all 535 biopsies was roughly $45,000; the estimated cost of six unnecessary prostatectomies would have been about $86,000, not counting lost wages, complications, or potential lawsuits.18PubMed. Clinical and cost impact of second-opinion pathology. Review of prostate biopsies prior to radical prostatectomy
Histologic Subtypes Outside of Cancer
Though cancer dominates the conversation, histologic subtyping shapes treatment and outcomes in several non-malignant diseases. Lupus nephritis, the kidney inflammation that affects many people with systemic lupus, is classified into distinct histologic classes based on what the kidney biopsy shows. The class determines both the treatment approach and the expected trajectory. Patients with one pattern of inflammation (class IV, diffuse proliferative) were about eight times more likely to enter remission than patients with other severe patterns, and their ten-year kidney survival was 75%, compared with around 47% to 52% for the other high-risk categories.19PubMed. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis Additional features visible on biopsy, like crescents, scarring, and inflammation of the tubules between the glomeruli, further refined the prediction of who would progress to kidney failure.20PubMed. Histological predictors of renal outcome in lupus nephritis: the importance of tubulointerstitial lesions and scoring of glomerular lesions
Lung fibrosis is another area where the histologic pattern is the diagnosis. Two patterns that can look similar on imaging, usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), carry very different prognoses. Patients with NSIP have significantly better survival and tend to maintain stable lung function, while those with UIP show progressive deterioration.21American Journal of Respiratory and Critical Care Medicine. A Histologic Pattern of Nonspecific Interstitial Pneumonia Is Associated with a Better Prognosis Than Usual Interstitial Pneumonia in Patients with Cryptogenic Fibrosing Alveolitis The distinction is not always easy. Advanced fibrotic NSIP can mimic UIP because it develops features traditionally considered hallmarks of UIP, such as honeycomb-like spaces and fibroblast foci, in up to a fifth of cases.22Modern Pathology. The histologic diagnosis of usual interstitial pneumonia of idiopathic pulmonary fibrosis. Where we are and where we need to go Misclassifying one as the other changes the treatment strategy and the conversation about what the patient can expect.
When Tumors Change Their Subtype
One of the more unsettling discoveries in recent cancer biology is that tumors can switch their histologic subtype under the pressure of treatment. This phenomenon, called lineage plasticity, involves cancer cells reprogramming themselves into a different cell type, sometimes abandoning the very characteristics that the targeted therapy was designed to exploit.23PubMed Central. Lineage plasticity in cancer: a shared pathway of therapeutic resistance
The best-documented example occurs in EGFR-mutant lung adenocarcinoma. Patients treated with tyrosine kinase inhibitors (drugs that specifically target the EGFR mutation) sometimes see their tumors transform into small cell lung cancer or other subtypes, losing their dependence on the original EGFR driver in the process.24PubMed Central. Lineage Plasticity and Histologic Transformation in EGFR-TKI Resistant Lung Cancer The transformed tumor no longer responds to the drug that was working, and its new identity requires a completely different treatment approach. Re-biopsy at the time of disease progression is increasingly recognized as necessary for exactly this reason: the subtype you started treating may not be the subtype you are dealing with when the cancer comes back.
Artificial Intelligence and the Future of Subtyping
Computational pathology is rapidly entering this space. Deep learning algorithms trained on digitized tissue slides can now classify histologic subtypes with remarkable accuracy. For gastric cancer, a deep learning model was able to stratify patients’ five-year survival better than the traditional pathologist-assigned classification system, even though the model and the pathologist frequently disagreed on which subtype a given case belonged to.25PubMed Central. Deep learning-based subtyping of gastric cancer histology predicts clinical outcome: a multi-institutional retrospective study In kidney cancer, multiple AI approaches tested head-to-head all achieved strong performance at distinguishing subtypes, suggesting the task is well-suited to automated analysis.26PubMed. Benchmarking weakly-supervised deep learning pipelines for whole slide classification in computational pathology
Beyond simple classification, AI tools are beginning to extract information from tissue slides that human eyes cannot directly perceive. One recent approach uses histopathology images to predict the composition of the tumor microenvironment, classifying tumors as “immune-inflamed” or “immune-desert” based on patterns in the tissue. These AI-derived subtypes predicted how well patients responded to immunotherapy, going beyond what standard measures alone could achieve.27npj precision oncology. Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images Research into how different histologic growth patterns correlate with immune signatures and immunotherapy outcomes is also advancing in lung adenocarcinoma.28PubMed Central. Transcriptional patterns reveal tumor histologic heterogeneity and immunotherapy response in lung adenocarcinoma
These tools will not replace pathologists in the near term, but they may reduce the variability that plagues difficult cases, flag ambiguous slides for additional review, and extract prognostic information that current manual methods miss.
The Problem of Rare Subtypes
For patients whose tumor falls into a rare histologic subtype, the usual infrastructure of evidence-based medicine starts to strain. Clinical trials depend on enrolling enough patients to detect a meaningful difference between treatments, and when a subtype affects only a small fraction of patients with a given cancer, recruitment can take years or become outright impossible. Trial designs for rare gynecologic tumors, for instance, require modified endpoints, adaptive statistical methods, and creative approaches to sample size just to answer basic questions about whether a therapy works.29PubMed. Clinical trial methodology in rare gynecologic tumor research: Strategies for success
One strategy is broadening eligibility. In rare central nervous system tumors, some first-in-human drug trials now enroll patients across a range of CNS cancer types during early phases to determine safe dosing, then narrow the focus to specific subtypes in later-phase studies.30PubMed Central. Clinical trial challenges, design considerations, and outcome measures in rare CNS tumors Another strategy relies on basket trials, where patients are grouped by molecular alteration rather than tumor location or histology. Neither approach is perfect, but both reflect the reality that rare subtypes cannot wait for traditional large-scale randomized trials.
For the patient, having a rare subtype often means fewer established treatment guidelines, less certainty about prognosis, and a greater reliance on molecular profiling to find an actionable target. It also means that participating in a clinical trial is not just an option but frequently the best available path to a treatment matched to their disease.
Where the Endometrial Example Gets Complicated
Endometrial cancer’s aggressive subtypes reveal a nuance worth understanding: even when subtypes overlap in survival, they can differ in biology in ways that have not yet translated into different treatments. Papillary serous endometrial cancer, for instance, shows frequent deletion of a specific chromosomal region (1p32-33) that is much less common in the more typical endometrioid type. This deletion points toward a tumor suppressor gene that may be specifically involved in the aggressive behavior of that subtype.31PubMed. Frequent deletion of chromosome 1p sequences in an aggressive histologic subtype of endometrial cancer Meanwhile, high-grade endometrial cancers of all subtypes remain difficult to treat, with recurrence rates around 20% and survival that remains poor despite aggressive combined therapy.32PubMed Central. High-Grade Endometrial Cancer-Behaviour and Outcomes at a Tertiary Cancer Centre
The implication is that histologic subtyping can identify biological differences that are real and measurable at the molecular level, even when the clinical impact of those differences is not yet exploitable with current treatments. That gap between what we can classify and what we can treat differently is closing, especially as molecular profiling catches up, but it has not closed everywhere. For some patients, the subtype on the pathology report is already the single most important factor in choosing a drug. For others, it is a piece of information that adds context but does not yet change the plan. The value of knowing remains high in both cases: you cannot target a difference you have not identified.